| Amicus Offers First Look At Gene Therapy Work With Batten’s Data | Ben Fidler | 08/01/19 | New York |
| How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy | Ben Fidler | 04/15/19 | National |
| Amicus Finally Wins FDA Nod, Will Price Fabry Drug Below Rivals | Ben Fidler | 08/10/18 | New York |
| Amicus Therapeutics’ Pompe Drug Data Show Improved Muscle Movement | Frank Vinluan | 10/04/17 | New York |
| Amicus Takes Aim at Rare Brain Disorder with MiaMed Acquisition | Frank Vinluan | 07/06/16 | New York |
| Amicus Nabs First Approval as EU Gives Green Light to Fabry Drug | Ben Fidler | 05/31/16 | New York |
| East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston |
| With Data in Hand, Amicus Preps For Drug Filings in U.S., Europe | Ben Fidler | 03/19/15 | New York |
| East Coast Biotech Roundup: NJ Blues, Genzyme, Amicus, Biogen & More | Ben Fidler | 08/25/14 | Boston |
| With Persistence And Phase 3 Win, Amicus Nears First Drug Approval | Ben Fidler | 08/20/14 | New York |
| East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More | Ben Fidler | 08/15/14 | Boston |
| Standing on a Ledge Once Again, Amicus Holds Breath for Latest Study | Ben Fidler | 08/11/14 | New York |
| Amicus Wheels, Deals, Restructures Following Fabry Drug Setback | Ben Fidler | 11/20/13 | New York |
| Amicus, Biogen Team Up on Parkinson’s Drug Deal | Ben Fidler | 09/10/13 | Boston |
| East Coast Life Sciences Roundup: IPO Madness, Amicus, & More | Ben Fidler | 06/21/13 | Boston |
| Amicus Shelves New-Drug Filing For Fabry Disease Drug | Ben Fidler | 06/17/13 | New York |
| Disease Foundations Play Growing Role in Biotech Business Model | Gail Maderis & Joe Panetta | 03/06/12 | San Francisco |
| Amicus Counts on “Chaperone” Tech to Enhance Rare Disease Treatments | Arlene Weintraub | 01/11/12 | New York |
